Blosozumab

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.^[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.^[2]

Blosozumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	SOST
Clinical data
ATC code	none
Identifiers
CAS Number	1132758-87-2 N
ChemSpider	none
UNII	83YOM0NEL5
KEGG	D10094 N
Chemical and physical data
Formula	C6462H9852N1684O2030S46
Molar mass	145086.42 g·mol−1
NY (what is this?)  (verify)

Blosozumab was developed by Eli Lilly and Company.